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Non-small cell lung cancers (NSCLCs) with activating mutations in
the kinase domain of the epidermal growth factor receptor (EGFR)
demonstrate dramatic, but transient, responses to the reversible
tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).
Some recurrent tumors have a common secondary mutation in the
EGFR kinase domain, T790M, conferring drug resistance, but in
other cases the mechanism underlying acquired resistance is un-
known. In studying multiple sites of recurrent NSCLCs, we detected
T790M in only a small percentage of tumor cells. To identify
additional mechanisms of acquired resistance to gefitinib, we used
NSCLC cells harboring an activating EGFR mutation to generate
multiple resistant clones in vitro. These drug-resistant cells dem-
onstrate continued dependence on EGFR and ERBB2 signaling for
their viability and have not acquired secondary EGFR mutations.
However, they display increased internalization of ligand-acti-
vated EGFR, consistent with altered receptor trafficking. Although
gefitinib-resistant clones are cross-resistant to related anilino-
quinazolines, they demonstrate sensitivity to a class of irreversible
inhibitors of EGFR. These inhibitors also show effective inhibition
of signaling by T790M-mutant EGFR and killing of NSCLC cells with
the T790M mutation. Both mechanisms of gefitinib resistance are
therefore circumvented by irreversible tyrosine kinase inhibitors.
Our findings suggest that one of these, HKI-272, may prove highly
effective in the treatment of EGFR-mutant NSCLCs, including tu-
mors that have become resistant to gefitinib or erlotinib.
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Gefitinib and erlotinib induce dramatic clinical responses incases of non-small cell lung cancers (NSCLCs) harboring
activating mutations in the EGF receptor (EGFR) (1–3), which is
targeted by these competitive inhibitors of ATP binding (4, 5). The
effectiveness of these tyrosine kinase inhibitors may result both
from alterations in the ATP cleft associated with these mutations,
which lead to enhanced inhibition of the mutant kinase by these
drugs, and from biological dependence of these cancer cells on the
increased survival signals transduced by the mutant receptors, a
phenomenon described as ‘‘oncogene addiction’’ (6, 7).
Although therapeutic responses to both gefitinib and erlotinib
can persist for as long as 2–3 years, the mean duration of response
in most cases of NSCLC is only 6–8 months (8–10). The mecha-
nisms underlying acquired drug resistance are not well understood.
By analogy with imatinib (Gleevec), which inhibits the BCR-ABL
kinase involved in chronic myeloid leukemias (CMLs), the C-KIT
kinase implicated in gastrointestinal stromal tumors (GISTs), and
the FIP1L1-PDGFR- kinase in idiopathic hypereosinophilic syn-
drome (HES), secondary kinase domain mutations can potentially
suppress drug binding (11–16). However, recurrent NSCLC is not
readily biopsied; hence, only limited clinical specimens are available
for analysis. Recently, a single secondary mutation, T790M, within
the EGFR kinase domain has been reported in three of six cases
with recurrent disease after gefitinib or erlotinib therapy (17, 18).
Codon 315 of BCR-ABL, which is analogous to EGFR codon 790,
is frequently mutated in imatinib-resistant CML (11, 12), and
mutation of the corresponding residue in C-KIT (codon 670) and
FIP1L1-PDGFR- (codon 674) is associatedwith imatinib-resistant
GIST and HES, respectively (15, 16). Early in vitro modeling of
resistance toEGFR inhibitors indicated thatmutation of codon 790
within the wild-type receptor would similarly suppress inhibition by
an EGFR tyrosine kinase inhibitor (19). Recently, transfected
EGFR proteins containing activating mutations together with the
T790M substitution were shown to exhibit reduced inhibition by
gefitinib and erlotinib (17, 18). Although the T790M mutation
seems to contribute to acquired resistance in some cases ofNSCLC,
the mechanisms underlying treatment failure in cases lacking
secondary EGFR mutations remain unexplained.
In contrast to the cytoplasmic kinase BCR-ABL, signaling by the
membrane-bound EGFR involves a complex pathway of ligand
binding, receptor homodimerization, and heterodimerization with
ERBB2 and other family members, followed by internalization and
recycling of the ligand-bound receptor or ubiquitin-mediated re-
ceptor degradation (20). Significant EGF-dependent signaling is
thought to occur during the process of internalization, which is also
associated with the dissociation of EGFR complexes at the low pH
of intracellular vesicles. As such, multiple factors modulate the
strength and quality of the signal transduced by the receptor, and
alterations in EGFR trafficking have been closely linked with the
regulation of EGF-dependent cellular responses (20).
Here, we show that even within recurrent gefitinib-resistant
NSCLCs containing the secondary T790M EGFR mutation, this
acquired mutation is only present in a subset of the resistant tumor
cells. In an in vitro model of acquired gefitinib resistance, the
T790M mutation is not observed, but increased EGFR internal-
ization is correlated with drug resistance. Irreversible inhibitors,
which covalently crosslink the receptor, are effective in cell lines
with the T790M mutation and in cells with altered EGFR traffick-
ing, raising the possibility that they may circumvent multiple
mechanisms of acquired resistance to gefitinib and erlotinib.
Methods
Analysis of Recurrent NSCLC and Generation of Gefitinib-Resistant
NCI-H1650 Cells. Clinical specimens of recurrent NSCLC were
obtained at autopsy after appropriate consent. The entire kinase
domain of EGFR was sequenced after analysis of uncloned PCR
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products. Multiple clones of exon 20 were sequenced to examine
codon 790. Mutational analysis of EGFR (exons 1–28), ERBB2
(exons 1–24), PTEN (exons 1–9), Kras (codons 12, 13, and 61), and
p53 (exons 5–8) in gefitinib-resistant clones as well as the parental
NCI-H1650 cell line was performed by automated sequencing of
individual exons and flanking intronic sequence (PCR conditions
available on request) with bidirectional sequencing by using dye
terminator chemistry (BIGDYE version 1.1, Applied Biosystems).
Sequencing reactions were run on an ABI3100 sequencer (Ap-
plied Biosystems), and electropherograms were analyzed by
using SEQUENCE NAVIGATOR and FACTURA software (Applied
Biosystems).
To generate resistant subclones of NCI-H1650 cells, these were
treated with ethyl methane sulfonate (EMS; 600gml), allowed to
recover for 72 h, and then seeded at a density of 6  104 cells per
10-cm2 dish in 20 M gefitinib. Relative resistance of these cells to
gefitinib, compared with the irreversible inhibitors, was achieved by
seeding 5  104 cells in six-well plates in 5% FCS and 100 ngml
EGF (Sigma), in the presence of varying concentrations of drugs,
followed after 72 h by fixing cells with 4% formaldehyde, staining
with 0.1% crystal violet, and quantifying cell mass by using the
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln,
NE). For small interferingRNA (siRNA) knockdown experiments,
cells were transfected with double-stranded RNA oligonucleotides
targeting EGFR, ERBB2 (both SMARTpool from Dharmacon,
Lafayette, CO), or nonspecific control (LRT1B), using X-treme
GENE transfection reagent (Roche Applied Science). After 72 h,
cells were stained with crystal violet and analyzed on the Odyssey
Infrared scanner.
Immunoblotting and Signaling Studies. Inhibition ofEGFR signaling
by increasing concentrations of gefitinib or the irreversible inhibi-
tors was determined by seeding 9  104 cells in 24-well plates,
adding the drugs to medium containing 5% FCS for 15 min,
followed by a 2-h pulse with 100 ngml EGF, and harvesting of
lysates. Lysates were prepared in 2 gel loading buffer, sonicated,
boiled, and then separated by 10% SDSPAGE, followed by
electrotransfer to polyvinylidene fluoride (PVDF)membranes, and
immunoblotting. Antibodies used were phospho-EGFRY1068 and
phospho-mitogen-activated protein kinase (MAPK) (Cell Signal-
ing Technology, Beverly, MA), phospho-AKT (BioSource Inter-
national, Camarillo, CA), and total EGFR, MAPK, AKT, and
tubulin (Santa Cruz Biotechnology).
Analysis of EGFR Internalization. To demonstrate internalization of
EGFR by fluorescence microscopy, cells were grown on coverslips
and incubated with 1 ngml recombinant human (rh) EGF (Mo-
lecular Probes, Eugene, OR) for various intervals before fixing in
4% paraformaldehyde for 10 min. Coverslips were washed in PBS
and mounted with ProLong Gold antifade reagent (Molecular
Probes). To quantify EGFR internalization by cell surface biotiny-
lation, cells were grown to confluency, pretreated with cyclohex-
amide, incubated on ice for 1 h with 1.5 mgml sulfosuccinimidyl-
2-(biotinamido)ethyl-1,3-dithiopropionate (sulfo-NHS-SS-biotin;
Pierce), and washed with blocking buffer (50 nM NH4CL1 mM
MgCl20.1 mMCaCl2 in PBS) to quench free sulfo-NHS-SS-biotin,
followed by several further washes with PBS. The cells were then
incubated in culture medium at 37°C for various intervals to allow
internalization of the biotinylated molecules, washed twice for 20
min in a glutathione solution (50 mM glutathione75 mMNaCl75
mMNaOH1%BSA) on ice to strip all of the biotinyl groups from
the cell surface, and then scraped and lysed in 500 M radioim-
munoprecipitation assay (RIPA) buffer (25 mM TrisHCl, pH 7.4,
with 150 mM NaCL0.1% SDS1% Triton X-100) supplemented
with NaF, Na-orthovanadate, and protease inhibitors. Cell extracts
were centrifuged, and the supernatants were incubated with
streptavidin beads (Sigma) to collect the biotinylated proteins,
whichwere then analyzed by SDSPAGEand immunoblotting with
Fig. 1. EGFR sequence analysis in recurrent metastatic lesions from two
NSCLC patients with acquired gefitinib resistance. (A) Case 1. The T790M
mutation in EGFR is present in a recurrent liver lesion after the develop-
ment of clinical gefitinib resistance. (Left) The mutation was not detected
in the primary lung lesion at the time of diagnosis. (Right) Both the primary
lung tumor and the recurrent liver lesion harbor the L858R gefitinib-
sensitizing mutation. Of note, the L858R mutation is present in the ex-
pected ratio for a heterozygous mutation in both primary and recurrent
lesions, whereas T790M is detectable at low levels compared with the
wild-type allele. A polymorphism (GA) is shown in the same tracing to
demonstrate equivalent representation of the two alleles in the uncloned
PCR product. (B) Case 2. The T790M mutation is present within a small
minority of gefitinib-resistant cells. (Left) The T790M mutation was unde-
tectable either in the lung primary tumor or in eight recurrent liver lesions
from this case by sequencing uncloned PCR products. Heterozygosity at an
adjacent polymorphism (GA) confirms amplification of both EGFR alleles
from these specimens. The heterozygous gefitinib-sensitizing mutation,
L861Q, was detected at the expected ratio within the primary lung tumor
as well as each of the eight recurrent liver lesions.
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anti-EGFR antibody (SC-03, Santa Cruz Biotechnology) or anti-
body against transferrin receptor (Santa Cruz Biotechnology).
Results and Discussion
Analysis of Recurrent Lung Cancers with Acquired Resistance to
Gefitinib. Recurrent gefitinib-resistant NSCLC developed in two
patients whose tumors had harbored an activating mutation of the
EGFR kinase at the time of diagnosis and who had shown a
dramatic initial clinical response to the drug (1). In both cases,
progressive metastatic disease in the liver led to the patients’
demises, 1–2 years after initiation of treatment. In case 1, analysis
of the major liver metastasis obtained at the time of autopsy
indicated persistence of the sensitizingEGFRmutation (L858R), as
well as the presence of a newly acquired T790Mmutation (Fig. 1A).
Interestingly, analysis of uncloned PCR products showed the initial
L858R mutation to be present at an abundance consistent with a
heterozygousmutation that is present in all tumor cells, whereas the
secondaryT790Mmutationwas seen at approximately one-fifth the
abundance of the corresponding wild-type allele. Thus, this resis-
tance-associated mutation seems to be present in only a fraction of
cells within the recurrent tumor.
Case 2 involved eight distinct recurrent metastases in the liver
after the failure of gefitinib therapy. In all of these independent
lesions, the sensitizing L861Q EGFR mutation was present at the
expected ratio for a heterozygous mutation. No secondary EGFR
mutation was detectable by analysis of uncloned PCR products
from any of these metastases. However, after subcloning of the
PCRproducts, the T790Mmutationwas found to be present at very
low frequency in two of the four metastatic tumors analyzed
(T790M, 2 of 50 clones sequenced from lesion 1 and 1 of 56 from
lesion 2), but not from two other recurrent metastases (0 of 55
clones from lesion 3 and 0 of 59 from lesion 4), or the primary tumor
(0 of 75 clones) (Fig. 1B and Table 1). Taken together, these results
are consistent with previous reports that the T790M mutation is
present in some, but not all, cases of acquired gefitinib resistance
(three of seven tumors; see refs. 17, 18, and 21). Furthermore, as
previously noted (18), even in some cases with this resistance-
associated mutation, it seems to be present in only a small fraction
of tumor cells within a recurrent lesion. These observations suggest
that additional mechanisms of resistance are involved in cases
without a secondary EGFR mutation and that such mechanisms
coexist with the T790M mutation in other cases.
Generation of Gefitinib-Resistant Cell Lines with Susceptibility to
Irreversible Inhibitors. Given the excellent correlation between the
clinical responsiveness of EGFR-mutantNSCLC and the enhanced
gefitinib-sensitivity of NSCLC cell lines with these mutations (2, 6,
22, 23), and the limited availability of clinical specimens from
relapsing patients, we modeled gefitinib resistance in vitro. We
cultured the bronchoalveolar cancer cell lineNCI-H1650, which has
an in-frame deletion of the EGFR kinase (delE746-A750), in 20
M gefitinib, either with or without prior exposure to the mutagen
ethyl methane sulfonate. This cell line exhibits 100-fold increased
sensitivity to gefitinib, compared with some NSCLC lines express-
ingwild-typeEGFR(6).Whereas the vastmajority of these cells are
efficiently killed by 20 M gefitinib, drug-resistant colonies were
readily observed at a frequency of 105, irrespective of mutagen
treatment. Forty-nine independent drug-resistant clones were iso-
lated, showing an average 50-fold decrease in gefitinib sensitivity
(Fig. 2A). All of these showed persistence of the sensitizing muta-
tion without altered expression of EGFR, and none had acquired
a secondary EGFR mutation or new mutations in ERBB2, p53,
Table 1. Presence of EGFR T790M mutation at very low
frequency in recurrent tumors from case 2
Tumor
No. of clones
T790M mutant Wild type
Primary 0 75
Recurrent 1 2 48
Recurrent 2 1 55
Recurrent 3 0 55
Recurrent 4 0 59
Sequencing of large numbers of cloned PCR products revealed that a
minority of alleles within two of four liver lesions contain the T790M
mutation.
Fig. 2. Acquired resistance to gefitinib in bronchoalveolar cancer cell lines
and persistent sensitivity to irreversible ERBB family inhibitors. (A) Inhibition
by tyrosine kinase inhibitors of proliferation of bronchoalveolar cancer cell
lines with wild-type EGFR (NCI-H1666), the activating delE746-A750 mutation
in EGFR (NCI-H1650), or two representative gefitinib-resistant subclones of
NCI-H1650 (G7 and C11). The effect of the reversible inhibitor gefitinib is
compared with that of the irreversible inhibitor HKI-357. Comparable results
were observed with the other irreversible inhibitors. Cell numbers were
measured by crystal violet staining, after culture in 5% FCS, with 100 ngml
EGFR, at 72 h after exposure to indicated drug concentrations. Each data point
represents the mean of four samples. (B) Chemical structure of gefitinib, a
reversible inhibitor of EGFR; EKB-569, an irreversible inhibitor of EGFR; and
HKI-272 and HKI-357, two irreversible dual inhibitors of EGFR and ERBB2. (C)
Generation of drug-resistant NCI-H1650 cells after treatment with varying
concentrations of gefitinib or the irreversible ERBB inhibitor EKB-569. Colo-
nies were stained after 12 days in culture in the presence of inhibitors.
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Kras, or PTEN (data not shown). Gefitinib-resistant clones dem-
onstrated comparable resistance to related inhibitors of the anili-
noquinazoline class (data not shown). Remarkably, however, they
displayed persistent sensitivity to three inhibitors of the ERBB
family (Fig. 2A and data not shown): HKI-272 (24) and HKI-357
(compound 7f in ref. 25), which are dual inhibitors of EGFR and
ERBB2 (IC50 values of 92 and 34 nM, respectively, for EGFR and
59 and 33 nM, respectively, for ERBB2), and EKB-569 (26), a
selective inhibitor of EGFR (IC50 values of 39 nM for EGFR and
1.3 M for ERBB2) (Wyeth) (Fig. 2B). All three drugs are
irreversible inhibitors, most likely via a covalent bond with the
cys773 residue within the EGFR catalytic domain or the cys805 of
ERBB2. Like gefitinib, these compounds demonstrate increased
killing of NSCLC cells harboring an EGFR mutation, compared
with cells expressing wild-type receptor (Fig. 2A). However, in
contrast to gefitinib, against which resistant clones are readily
generated, even at high drug concentrations, we were unable to
establish clones of cells that were resistant to the irreversible
inhibitors at concentrations above 10M, even after ethyl methane
sulfonate mutagenesis (Fig. 2C).
Dependence of Gefitinib-Resistant Cells on EGFR and ERBB2 Expres-
sion. To gain insight into the mechanisms underlying the acqui-
sition of gefitinib resistance and the persistent sensitivity to the
irreversible inhibitors, we first determined whether resistant cell
lines remain dependent upon EGFR for their viability. We have
previously shown that siRNA-mediated knockdown of EGFR
triggers apoptosis in cells harboring mutant EGFRs, but not in
those with wild-type alleles (6). Significantly, parental NCI-
H1650 cells as well as their gefitinib-resistant derivatives showed
comparable reduction in cell viability after transfection with
siRNA targeting EGFR (Fig. 3A). Thus, acquisition of gefitinib-
resistance does not involve EGFR-independent activation of
downstream effectors. Because HKI-272 and HKI-357 target
both EGFR and ERBB2, we also tested suppression of this
related receptor. Knockdown of ERBB2 in NCI-H1650 and its
gefitinib-resistant derivatives also caused loss of viability (Fig.
3A), suggesting a role for EGFR–ERBB2 heterodimers in
transducing essential survival signals in tumor cells harboring
EGFR mutations. Inhibition of EGFR alone by an irreversible
inhibitor seems to be sufficient to induce apoptosis in gefitinib-
resistant cells, as demonstrated by the effectiveness of EKB-569,
which primarily targets EGFR (26). However, given the poten-
tially complementary effects of targeting both EGFR and
ERBB2 by using siRNA and the availability of irreversible
inhibitors that target both of these family members, the potential
benefit of dual inhibition warrants consideration.
We compared the ability of gefitinib and irreversible ERBB
family inhibitors to suppress signaling via downstream effec-
tors of EGFR that mediate its proliferative and survival
pathways. HKI-357 was 10-fold more effective than gefitinib in
suppressing EGFR autophosphorylation (measured at residue
Y1068), and AKT and MAPK phosphorylation in parental
NCI-H1650 cells harboring the delE746-A750 EGFRmutation
(Fig. 3B). In a gefitinib-resistant derivative, NCI-H1650(G7),
gefitinib exhibited considerably reduced efficacy in suppress-
Fig. 3. Persistent dependence on EGFR and ERBB2 signaling
in gefitinib-resistant cells, and altered receptor trafficking. (A)
Cell viability after siRNA-mediated knockdown of EGFR and
ERBB2 in bronchoalveolar cell lines with wild-type EGFR (NCI-
H1666), compared with cells with the activating delE746-A750
mutation in EGFR (NCI-H1650) and two gefitinib-resistant
derivatives (G7 and C11). Viable cells were counted 72 h after
treatment with double-stranded RNA and are shown as a
fraction relative to cells treated with nonspecific siRNA, with
standard deviations based on triplicate samples. (B) Inhibition
of EGFR autophosphorylation (Y1068) and phosphorylation of
downstream effectors AKT and MAPK (ERK) in cells treated
with increasing concentrations of gefitinib or the irreversible
inhibitor HKI-357, followed by a 2-h pulse with EGF. The
parental cell line NCI-H1650 is compared with a representative
gefitinib-resistant line, G7. Total AKT and MAPK are shown as
controls; tubulin is used as loading control for total EGFR
levels, which are at the lower limit of detection in these cells.
(C) Altered EGFR internalization in gefitinib-resistant NCI-
H1650 (G7) cells, compared with the sensitive NCI-H1650 pa-
rental cell line. Rhodamine-tagged EGF is used to label EGFR at
5 and 20 min, after addition of ligand. The increased internal-
ization of EGFR in NCI-H1650 (G7) cells is most evident at 20
min. (Zeiss microscope, 63 magnification). (D) Immunoblot-
ting of internalized EGFR from NCI-H1650 parental cells and
the resistant derivative G7 after pulse labeling of cell surface
proteins by biotinylation and chase over 20 min. The increased
intracellular EGFR in NCI-H1650 (G7) cells is compared with the
unaltered transferrin receptor (TR) internalization.
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ing AKT phosphorylation, a key EGFR signaling effector
linked to gefitinib responsiveness (6), whereas HKI-357 dem-
onstrated persistent activity (Fig. 3B).
Altered EGFR Internalization in Gefitinib-Resistant Clones. Given the
absence of secondary mutations in EGFR and the persistent
susceptibility of gefitinib-resistant cells to siRNA-mediated sup-
pression of EGFR, we tested whether the mechanism underlying
the differential inhibition of EGFR signaling in gefitinib-resistant
cells by reversible and irreversible inhibitors might be correlated
with alterations in receptor trafficking, a well documented modu-
lator of EGFR-dependent signaling (20). Indeed, analysis of EGFR
trafficking in NCI-H1650-derived resistant cells demonstrated a
consistent increase in EGFR internalization, compared with the
parental drug-sensitive cells, as measured both by internalization of
fluorescein-labeled EGF (Fig. 3C) and quantitation of cytoplasmic
biotinylated EGFR (Fig. 3D). No such effect was observed with the
transferrin receptor, suggesting that this did not result from a
generalized alteration in all receptor processing. Although further
work is required to define the precise mechanism for this alteration
in EGFR trafficking, a complex process in which numerous regu-
latory proteins have been implicated, these results suggest that
gefitinib’s ability to inhibit EGFR activation is compromised in
these cells, whereas the action of the irreversible inhibitors are not
detectably affected.
Inhibition of T790M EGFR Signaling and Enhanced Cell Killing by
Irreversible Inhibitors. The enhanced suppression of EGFR sig-
naling by irreversible ERBB inhibitors raised the possibility
that these drugs may also exhibit persistent activity in the
context of cells harboring the T790M secondary mutation in
EGFR. We therefore tested the effect of these inhibitors on
the NCI-H1975 bronchoalveolar cancer cell line, which har-
bors both L858R and T790M mutations in EGFR (18). Sig-
nificantly, this cell line was derived from a patient that had not
been treated with an EGFR inhibitor, indicating that this
mutation is not uniquely associated with acquired drug resis-
tance. Both HKI-357 and HKI-272 were considerably more
effective than gefitinib in suppressing ligand-induced EGFR
autophosphorylation and its downstream signaling, as deter-
mined by AKT and MAPK phosphorylation (Fig. 4A). Simi-
larly, all three irreversible inhibitors suppressed proliferation
in this cell line under conditions where it is resistant to
gefitinib (Fig. 4B). Thus, irreversible ERBB inhibitors seem to
be effective in cells harboring the T790M EGFR as well as in
cells with altered trafficking of the wild-type receptor.
Conclusion
Our results confirm the report of T790M mutations in EGFR
as secondary mutations that arise in previously sensitive
NSCLCs harboring an activating mutation, associated with the
emergence of acquired resistance (17, 18). However, this
mutation is present only in a subset of cases, and even tumors
that harbor the T790M mutation may contain only a small
fraction of cells with this mutation. These observations imply
that multiple resistance mechanisms can coexist in recurrent
tumors after an initial response to gefitinib or similar revers-
ible EGFR inhibitors. Moreover, these findings suggest that
T790M-independent resistance mechanisms may be equally, if
not more, effective than the T790M substitution itself in
conferring drug resistance and may explain why recurrent
tumors rarely exhibit clonality for T790M (17, 18). In vitro
mechanisms of acquired gefitinib resistance do not involve
secondary EGFR mutations at a significant frequency, but
instead are correlated with altered receptor trafficking. How-
ever, it should be noted that we have not examined EGFR
trafficking in all of the resistant clones that we established in
vitro, and it remains possible that additional mechanisms may
contribute to gefitinib resistance in some of the clones.
Nonetheless, virtually all gefitinib-resistant clones exhibited
comparable sensitivity to the irreversible ERBB inhibitors.
Our results indicate striking differences between competi-
tive EGFR inhibitors such as gefitinib, whose effectiveness is
limited by the rapid development of drug resistance in vitro,
and irreversible inhibitors, to which acquired resistance ap-
pears to be rare (Fig. 2C). We speculate that increased
internalization of ligand-bound EGFR in resistant cells may be
linked to dissociation of the gefitinib–EGFR complex at the
low pH of intracellular vesicles. In contrast, irreversible cross-
linking of the receptor would be unaffected by such alterations
in receptor trafficking. Acquired resistance to gefitinib is
stably maintained after passage of cells for up to 20 genera-
tions in the absence of drug, suggesting that genetic or
epigenetic alterations in genes that modulate EGFR turnover
may underlie this phenomenon. Because receptor trafficking
cannot be readily studied by using available clinical specimens,
identification of such genomic alterations may be required
before clinical correlations are possible. Nonetheless, such a
mechanism may contribute to in vivo acquired gefitinib-
resistance in patients with recurrent disease who do not have
secondary mutations in EGFR.
Of the three irreversible ERBB inhibitors described here,
both HKI-272 and EKB-569 have been subjected to phase I
clinical testing. Clinical studies in EGFR mutant NSCLC are
required to determine whether these drugs have persistent
activity in NSCLC cases that have become refractory to
gefitinib or erlotinib and whether they potentially induce
longer lasting responses in untreated patients. If validated in
such clinical trials, the design of additional irreversible ty-
rosine kinase inhibitors targeting cancer-associated receptor
tyrosine kinases may warrant consideration.
Fig. 4. Effectiveness of irreversible ERBB inhibitors in suppressing the T790M
EGFR mutant. (A) Comparison of gefitinib and two irreversible inhibitors,
HKI-357 and HKI-272, in their ability to suppress EGFR autophosphorylation
(Y1068) and phosphorylation of downstream effectors AKT and MAPK (ERK)
in the NCI-H1975 bronchoalveolar cell line, harboring both a sensitizing
mutation (L858R) and the resistance-associated mutation (T790M). Total
EGFR, AKT, and MAPK are shown as loading controls. (B) Suppression of
proliferation in NCI-H1975 cells harboring the L858R and T790M mutations by
the three irreversible ERBB family inhibitors, compared with gefitinib.
Kwak et al. PNAS  May 24, 2005  vol. 102  no. 21  7669
M
ED
IC
A
L
SC
IE
N
CE
S
Note. Irreversible ERBB inhibitors also seem to be effective in over-
coming gefitinib resistance mediated by the T790M mutation, an effect
that presumably results from the preservation of inhibitor binding
despite alteration of this critical residue. While this work was in progress,
another irreversible inhibitor of EGFR [CL-387,785, Calbiochem (27)]
was shown to inhibit the kinase activity of the T790MEGFRmutant (17).
The effectiveness of CL-387,785 in the context of T790M was proposed
to result from the absence of a chloride at position 3 of the aniline group,
which is present in gefitinib and was postulated to interfere sterically with
binding to the mutant methionine at codon 790. However, EKB-569,
HKI-272, and HKI-357 all have chloride moieties at that position in the
aniline ring, suggesting that their shared ability to bind irreversibly to
EGFR is likely to explain their effectiveness, rather than the absence of
a specific steric interaction with T790M (24–26). Thus, these irreversible
inhibitors may prove to be broadly effective in circumventing a variety
of resistance mechanisms, in addition to the T790M mutation.
We thank Drs. Lee Greenberger, Bruce Chabner, and David Louis for
helpful comments. This work was supported by National Institutes of
Health Grant PO1 95281 (to D.A.H. and D.W.B.), the Doris Duke
Charitable Foundation (to D.A.H.), the Sandler Family Foundation (to
D.A.H. and D.W.B.), the V Foundation Award (to J.S.), the Samuel
Waxman Cancer Research Foundation (to J.S.), the Saltonstall Schol-
arship (to J.S.), the Cole-Angelus Fund, the Romaine Fund, and Sue’s
Fund for lung cancer research (to T.J.L.).
1. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A.,
Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G.,
et al. (2004) N. Engl. J. Med. 350, 2129–2139.
2. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman,
P., Kaye, F. J., Lindeman N., Boggon, T. J., et al. (2004) Science 304, 1497–1500.
3. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh,
B., Rusch, V., Fulton, L., Mardis, E., et al. (2004) Proc. Natl. Acad. Sci. USA
101, 13306–13311.
4. Wakeling, A. E., Guy, S. P.,Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker,
A. J. & Gibson, K. H. (2002) Cancer Res. 62, 5749–5754.
5. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunning-
ham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., et al. (1997) Cancer
Res. 57, 4838–4848.
6. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. (2004) Science 305,
1163–1167.
7. Weinstein, I. B. (2002) Science 297, 63–64.
8. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.,
Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) J. Clin.
Oncol. 12, 2237–2246.
9. Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, T. J., Prager, D., Belani, C. P.,
Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) J. Amer. Med.
Assoc. 290, 2149–2158.
10. Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman,
M., Karp, D., Rigas, J., Clark, G. M., Santabarbara, P. & Bonomi, P. (2004)
J. Clin. Oncol. 22, 3238–3247.
11. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, N. &
Sawyers, C. L. (2001) Science 293, 876–880.
12. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan,
J. & Sawyers, C. L. (2002) Cancer Cell 2, 117–125.
13. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. & Sawyers, C. L. (2004)
Science 305, 399–401.
14. Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W.,
Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) Cancer
Res. 64, 5913–5919.
15. Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A.,
Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004)
Gastroenterology 127, 294–299.
16. Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J.,
Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) New Engl. J. Med.
348, 1201–1214.
17. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson,
M., Johnson, B. E., Eck, M. J., Tenen, D. G. & Halmos, B. (2005) N. Engl.
J. Med. 352, 786–792.
18. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F.,
Kris, M. & Varmus, H. (2005) PLoS Med. 2, 1–11.
19. Blencke, S., Ullrich, A. & Daub, H. (2003) J. Biol. Chem. 278, 15435–
15440.
20. Wiley, H. S. (2003) Exp. Cell Res. 284, 78–88.
21. Amann, J., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shige-
matsu, H., Peyton, M., Juroske, D., Huang, Y., Stuart Salmon, J., et al. (2005)
Cancer Res. 65, 226–235.
22. Tracy S., Mukohara, T., Hansen, M., Meyerson, M., Johnson, B. E. & Janne,
P. A. (2004) Cancer Res. 64, 7241–7244.
23. Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N. & Nishio, K. (March 10,
2005) Int. J. Cancer, 10.1002ijc.20985.
24. Rabindran, S. K., Discafani, C. M., Rosfjord, E. C., Baxter, M., Floyd, M. B.,
Golas, J., Hallett, W. A., Johnson, B. D., Nilakantan, R., Overbeek, E., et al.
(2004) Cancer Res. 64, 3958–3965.
25. Tsou, H., Overbeek-Klumpers, E. G., Hallett, W. A., Reich,M. F., Floyd,M. B.,
Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al.
(2005) J. Med. Chem. 48, 1107–1131.
26. Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B.,
Wissner, A., Nunes, M., Frost, P. & Discafani, C. M. (2000) Nat. Med. 6,
1024–1028.
27. Discafani, C. M., Carroll, M. L., Floyd, M. B., Jr., Hollander, I. J., Husain, Z.,
Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., Jr., et
al. (1999) Biochem. Pharmacol. 57, 917–925.
7670  www.pnas.orgcgidoi10.1073pnas.0502860102 Kwak et al.
